Synthesis of psoralidin (cas 18642-23-4) derivatives and their anticancer activity: first synthesis of Lespeflorin I1
-
Add time:09/27/2019 Source:sciencedirect.com
Synthetic scheme for the preparation of a number of different derivatives of anticancer natural product psoralidin (cas 18642-23-4) is described. A convergent synthetic approach is followed using simple starting materials like substituted phenyl acetic esters and benzoic acids. The developed synthetic route leads us to complete the first synthesis of an analogous natural product Lespeflorin I1, a mild melanin synthesis inhibitor. Preliminary bioactivity studies of the synthesized compounds are carried out against two commonly used prostate cancer cell lines. Results show that the bioactivity of the compounds can be manipulated by the simple modification of the functional groups.
We also recommend Trading Suppliers and Manufacturers of psoralidin (cas 18642-23-4). Pls Click Website Link as below: cas 18642-23-4 suppliers
Prev:Comparison of the in vitro metabolism of psoralidin (cas 18642-23-4) among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes
Next:Pharmaceutical NanotechnologyNanoencapsulation of psoralidin (cas 18642-23-4) via chitosan and Eudragit S100 for enhancement of oral bioavailability) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- psoralidin (cas 18642-23-4), a coumestan analogue, as a novel potent estrogen receptor signaling molecule isolated from Psoralea corylifolia09/28/2019
- Pharmaceutical NanotechnologyNanoencapsulation of psoralidin (cas 18642-23-4) via chitosan and Eudragit S100 for enhancement of oral bioavailability10/01/2019
- Comparison of the in vitro metabolism of psoralidin (cas 18642-23-4) among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes09/26/2019
- RESEARCH ARTICLE: Pharmacokinetics, Pharmacodynamics and Drug Transport and MetabolismRegio- and Isoform-Specific Glucuronidation of psoralidin (cas 18642-23-4): Evaluation of 3-O-Glucuronidation as a Functional Marker for UGT1A909/25/2019
- Molecular and cellular pharmacologypsoralidin (cas 18642-23-4), a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts09/24/2019
- psoralidin (cas 18642-23-4) suppresses osteoclastogenesis in BMMs and attenuates LPS-mediated osteolysis by inhibiting inflammatory cytokines09/10/2019
- The higher osteoprotective activity of psoralidin (cas 18642-23-4) in vivo than coumestrol is attributed by its presence of an isopentenyl group and through activated PI3K/Akt axis09/09/2019
- Original ArticleEffect and mechanism of psoralidin (cas 18642-23-4) on promoting osteogenesis and inhibiting adipogenesis09/08/2019
- ReviewMechanisms explaining the efficacy of psoralidin (cas 18642-23-4) in cancer and osteoporosis, a review09/07/2019